Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Paul Richardson: Isatuximab Improves PFS in Relapsed/Refractory Myeloma

December 30, 2021

Paul Richardson, MD, shares results seen with isatuximab in heavily refractory myeloma, and discusses how this new agent compares with approved monoclonal antibodies.

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
November 2024

Advertisement intended for health care professionals

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals